retatrutide (LY3437943) - Eli Lilly
Mounjaro (tirzepatide) - Eli Lilly
Zepbound (tirzepatide) - Eli Lilly
Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search. (PubMed, Rev Endocr Metab Disord) - Oct 23, 2026 - "These observations may help explain the efficacy of dual and triple incretin receptor agonists, including tirzepatide and retatrutide, which produce significant improvements in body weight and metabolic outcomes. Collectively, current evidence supports a depot-specific and context-dependent role of GIP in adipose tissue biology and underscores the therapeutic potential of targeting the GIP/GIPR axis in obesity and metabolic disease." 
Journal • Review • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity
http://www.ncbi.nlm.nih.gov/pubmed/42907720
 
Joanna Smarkusz-Zarzecka; Krzysztof Ksawery Gofron; Lucyna Ostrowska; Marcelina Radziszewska
 
Oct 23, 2026
 
Prev Next